The CHRYSALIS study (NCT02609776) is evaluating amivantamab, a fully human bispecific antibody that targets epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET) mutations, zin combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in patients with non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.

Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1), clinical benefit rate, duration of response and the safety profile of amivantamab and lazertinib, in the 91 patients treated with the combination across dose escalation and expansion cohorts.

The study results were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract #1258O) as an oral presentation.

Results from the CHRYSALIS study have led to new studies to further evaluate the potential of amivantamab and lazertinib combination therapy.

The CHRYSALIS study is an open-label, global, multicentre study evaluating the safety, pharmacokinetics and efficacy of amivantamab as a monotherapy and in combination with lazertinib in adult patients with advanced NSCLC.

Exon 19 deletion and L858R mutations are common, accounting for 85 percent of all EGFR mutations in NSCLC.

In the study, 91 patients with NSCLC harbouring EGFR exon 19 deletion or L858R mutations received the combination of amivantamab intravenously and lazertinib orally.

The study enrolled 26 patients in dose escalation and identified a combination dose that was equivalent to monotherapy doses of both products.

Additionally, 20 treatment-naïve patients with EGFR-mutated NSCLC were enrolled to further examine the safety, efficacy and tolerability in the first-line setting and 45 patients who had relapsed on osimertinib but were chemotherapy-naïve were enrolled to examine safety and efficacy in the resistance setting.

In the treatment-naïve group, 20 patients receiving the combination of amivantamab and lazertinib achieved a 100 percent ORR (95 percent CI, 83 – 100).

The median follow-up and treatment duration at the time of data cut-off was seven months (range 4 – 10).

Among 45 osimertinib-relapsed, chemotherapy-naïve patients, the combination of amivantamab and lazertinib resulted in a 36 percent ORR (95 percent CI, 22 – 51), with one complete response and 15 partial responses.

The clinical benefit rate for these patients was 60 percent (95 percent CI, 44 – 74).

Biomarker and central nervous system analyses and efficacy by mechanism of osimertinib resistance are ongoing and will be presented at a future medical meeting.

“Despite treatment advancements, lung cancer remains the leading cause of cancer deaths globally, and there are opportunities to improve treatment options for patients with non-small cell lung cancer with genetic factors such as EGFR mutations,” said Byoung Chul Cho, M.D., Ph.D., Yonsei Cancer Centre, Yonsei University College of Medicine in Seoul, South Korea, and lead study investigator.

“We are encouraged by these results that suggest amivantamab in combination with lazertinib may be a promising option in this specific disease cohort where a high unmet need remains for more targeted treatment options.” 

For the 91 treated patients, the majority of treatment-related adverse events (AEs) experienced were Grade 1-2.

A low incidence of Grade ≥3 treatment-related AEs occurred, which included rash (four percent), hypoalbuminemia (two percent), increased gamma glutamyltransferase (one percent), hyponatraemia (one percent) paronychia (one percent) and interstitial lung disease (one percent).

Related AEs leading to treatment discontinuation occurred in six percent of patients.

Infusion-related reaction occurred predominantly at first infusion and did not impact subsequent dosing.

The results from the CHRYSALIS study have led to new studies to further evaluate the potential of amivantamab and lazertinib combination therapy.

The Phase 3 MARIPOSA study (NCT04487080) will assess the amivantamab and lazertinib combination versus osimertinib in previously untreated advanced EGFR-mutated NSCLC, and a Phase 1 trial (NCT04077463) has been initiated to examine the combination in patients who have progressed after treatment with osimertinib and chemotherapy.

“Lung cancer is the biggest cause of cancer death in Europe and has one of the lowest five-year survival rates for cancer patients. At Janssen, we are committed to developing innovative targeted therapies that address the unmet needs for specific types of lung cancer, such as those with EGFR-mutated non-small cell lung cancer,” said Joaquín Casariego, M.D., Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag, S.A.

“The interim data from the evaluation of amivantamab and lazertinib in combination demonstrate encouraging potential for providing new treatment options for the advanced NSCLC patient population.”

Source: Janssen